Skip to main content
Clinical Trials/NCT04724681
NCT04724681
Terminated
Not Applicable

Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection

University Hospital Bispebjerg and Frederiksberg1 site in 1 country97 target enrollmentNovember 3, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Clinical Deterioration
Sponsor
University Hospital Bispebjerg and Frederiksberg
Enrollment
97
Locations
1
Primary Endpoint
Cumulative duration of deviating vital signs, respiratory rate ≤ 5 min-1
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

For patients admitted with COVID-19 infection, it is often difficult to predict if or when their clinical condition will deteriorate. However subtle changes in vital signs are usually present 8 to 24 hours before a life-threatening event such as respiratory failure leading to ICU admission, or unanticipated cardiac arrest. Such adverse trends in clinical observations can be missed, misinterpreted or not appreciated as urgent. New continuous and wearable 24/7 clinical vital parameter monitoring systems offer a unique possibility to identify clinical deterioration before patients condition progress beyond the point-of-no-return, where adverse events are inevitable. The primary aim of this study is to test the effect of continuous wireless vital signs monitoring with generation of real-time alerts through a purpose-built GUI, compared to standard EWS monitoring on the cumulative duration of any severely deviating vital signs

Registry
clinicaltrials.gov
Start Date
November 3, 2020
End Date
December 31, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital Bispebjerg and Frederiksberg
Responsible Party
Principal Investigator
Principal Investigator

Katja Kjær Grønbæk

Principal Investigator

University Hospital Bispebjerg and Frederiksberg

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Cumulative duration of deviating vital signs, respiratory rate ≤ 5 min-1

Time Frame: up to 16 days

Cumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Respiratory rate ≤ 5 min-1

Cumulative duration of deviating vital signs, respiratory rate > 24 min-1

Time Frame: up to 16 days

Cumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Respiratory rate \> 24 min-1

Cumulative duration of deviating vital signs: SpO2 < 85% min-1

Time Frame: up to 16 days

Cumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● SpO2 \< 85% min-1

Cumulative duration of deviating vital signs, heart rate > 130 min-1

Time Frame: up to 16 days

Cumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Heart rate \> 130 min-1

Cumulative duration of deviating vital signs, ScO2

Time Frame: up to 16 days

Cumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Lowest ScO2 (mean for ≥ 5 mins) min-1

Cumulative duration of deviating vital signs, heart rate ≤ 30 min-1

Time Frame: up to 16 days

Cumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Heart rate ≤ 30 min-1

Secondary Outcomes

  • Change in vital parameters(up to 16 days)
  • The frequency of events with desaturation as defined below and the simultaneous values of ScO2(up to 16 days)
  • Frequency of predefined microevents (deviating vital signs)(up to 16 days)
  • Events with ScO2 < 60% for ≥ 1 min(up to 16 days)

Study Sites (1)

Loading locations...

Similar Trials